Ashley Dombkowski, Alladapt CEO

Al­ladapt gets $100M+ to see its all-in-one oral im­munother­a­py al­ler­gy drug through clin­i­cal tri­als

Most food al­ler­gy care in­volves avoid­ance — check­ing in­gre­di­ent la­bels, no peanut ta­bles in schools, and so on. How­ev­er, that par­a­digm has been shift­ing with oral …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.